Profile data is unavailable for this security.
About the company
Invivyd, Inc. is a commercial-stage company, which is engaged in delivering antibody-based therapies. The Company’s proprietary INVYMAB platform approach combines state-of-the-art viral surveillance and predictive modeling with advanced antibody engineering. INVYMAB is designed to facilitate the rapid, serial generation of new monoclonal antibodies (mAbs) to keep pace with evolving viral threats. The Company delivers antibody-based therapies that protect vulnerable people from the devastating consequences of circulating viral threats, such as SARS-CoV-2 (COVID-19). Its PEMGARDA is the Company’s first mAb in a planned series of innovative mAb candidates designed to keep pace with SARS-CoV-2 viral evolution. Its VYD2311 is optimized for neutralization potency against recent SARS-CoV-2 lineages such as BA.2.86 and JN.1. The Company also has additional anti-SARS-CoV-2 mAb candidates in discovery and pre-clinical characterization.
- Revenue in USD (TTM)2.26m
- Net income in USD-203.84m
- Incorporated2020
- Employees94.00
- LocationInvivyd Inc1601 Trapelo Road, Suite 178WALTHAM 02451United StatesUSA
- Phone+1 (781) 819-0080
- Fax+1 (302) 655-5049
- Websitehttps://invivyd.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Adicet Bio Inc | 0.00 | -117.88m | 107.95m | 143.00 | -- | 0.5103 | -- | -- | -1.70 | -1.70 | 0.00 | 2.57 | 0.00 | -- | -- | 0.00 | -49.20 | -37.03 | -53.58 | -40.28 | -- | -- | -- | -748.46 | -- | -- | 0.00 | -- | -100.00 | -- | -104.41 | -- | 65.27 | -- |
| Karyopharm Therapeutics Inc | 148.44m | -87.48m | 109.32m | 325.00 | -- | -- | -- | 0.7365 | -0.7906 | -0.7906 | 1.17 | -1.27 | 0.6462 | 1.58 | 4.26 | 456,744.60 | -38.08 | -53.02 | -52.09 | -65.85 | 95.85 | 97.18 | -58.93 | -125.15 | 2.93 | -5.25 | 2.53 | -- | -7.03 | 36.93 | 13.43 | -- | -- | -- |
| ENDRA Life Sciences Inc | 0.00 | -9.57m | 109.93m | 21.00 | -- | 0.0279 | -- | -- | -1,597.14 | -1,597.14 | 0.00 | 217.30 | 0.00 | -- | -- | 0.00 | -97.17 | -132.00 | -117.34 | -157.28 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 23.67 | -- | -19.46 | -- |
| Anixa Biosciences Inc | 0.00 | -12.36m | 110.70m | 4.00 | -- | 5.08 | -- | -- | -0.3906 | -0.3906 | 0.00 | 0.6772 | 0.00 | -- | -- | 0.00 | -50.54 | -59.69 | -52.50 | -62.61 | -- | -- | -- | -6,040.10 | -- | -- | 0.00 | -- | -- | -28.36 | 27.83 | -- | -- | -- |
| Invivyd Inc | 2.26m | -203.84m | 115.26m | 94.00 | -- | 0.8195 | -- | 50.91 | -1.80 | -1.80 | 0.0199 | 1.18 | 0.0092 | -- | 1.13 | 24,085.11 | -82.73 | -- | -96.25 | -- | 96.11 | -- | -9,003.40 | -- | 4.57 | -- | 0.00 | -- | -- | -- | 17.68 | -- | -- | -- |
| Alto Neuroscience Inc | -100.00bn | -100.00bn | 115.65m | 78.00 | -- | 0.6431 | -- | -- | -- | -- | -- | 6.67 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.053 | -- | -- | -- | -31.02 | -- | -- | -- |
| Fennec Pharmaceuticals Inc | 48.89m | 2.74m | 117.37m | 36.00 | 110.28 | -- | 42.92 | 2.40 | 0.0389 | 0.0389 | 1.75 | -0.0497 | 1.18 | 1.21 | 6.63 | -- | 6.62 | -73.43 | 7.70 | -84.32 | 95.55 | -- | 5.59 | -383.28 | 7.75 | 1.87 | 1.05 | -- | 1,284.50 | -- | 32.34 | -- | -- | -- |
| Fractyl Health Inc | 119.00k | -65.88m | 118.38m | 102.00 | -- | 1.67 | -- | 994.79 | -1.37 | -1.37 | 0.0025 | 1.48 | 0.0013 | 1.02 | 3.05 | 1,166.67 | -59.97 | -- | -67.93 | -- | 41.18 | -- | -46,620.17 | -- | 7.46 | -- | 0.2862 | -- | -- | -- | -48.15 | -- | -- | -- |
| Allakos Inc | 0.00 | -178.75m | 119.95m | 131.00 | -- | 1.66 | -- | -- | -2.03 | -2.03 | 0.00 | 0.8142 | 0.00 | -- | -- | 0.00 | -87.64 | -42.71 | -97.01 | -45.11 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 41.96 | -- | -38.89 | -- |
| Coya Therapeutics Inc | 9.55m | -10.10m | 120.46m | 8.00 | -- | 3.11 | -- | 12.61 | -0.7726 | -0.7726 | 0.7589 | 2.32 | 0.3512 | -- | -- | 1,194,290.00 | -37.13 | -- | -40.92 | -- | -- | -- | -105.71 | -- | -- | -- | 0.00 | -- | -- | -- | 34.77 | -- | -- | -- |
| PDS Biotechnology Corp | 0.00 | -40.68m | 121.14m | 25.00 | -- | 3.91 | -- | -- | -1.23 | -1.23 | 0.00 | 0.8406 | 0.00 | -- | -- | 0.00 | -65.48 | -51.63 | -80.82 | -59.00 | -- | -- | -- | -- | -- | -21.59 | 0.4409 | -- | -- | -- | -5.11 | -- | -- | -- |
| Seres Therapeutics Inc | 374.00k | -162.11m | 121.73m | 233.00 | -- | -- | -- | 325.47 | -1.18 | -1.18 | 0.0027 | -0.5742 | 0.001 | -- | 0.0286 | 1,605.15 | -44.53 | -41.51 | -59.82 | -54.13 | -- | -- | -43,343.58 | -170.14 | 0.889 | -17.64 | 6.65 | -- | 1,672.24 | 34.91 | 54.54 | -- | 32.72 | -- |
| Century Therapeutics Inc | 2.69m | -129.89m | 122.44m | 152.00 | -- | 0.6222 | -- | 45.60 | -1.86 | -1.86 | 0.0372 | 2.31 | 0.0068 | -- | -- | 17,664.47 | -33.04 | -- | -34.83 | -- | -- | -- | -4,837.73 | -- | -- | -- | 0.00 | -- | -57.01 | -- | -4.38 | -- | -- | -- |
| Leap Therapeutics Inc | 0.00 | -60.34m | 123.98m | 54.00 | -- | 1.88 | -- | -- | -2.00 | -2.00 | 0.00 | 1.72 | 0.00 | -- | -- | 0.00 | -67.81 | -80.06 | -80.19 | -95.03 | -- | -- | -- | -7,900.37 | -- | -- | 0.00 | -- | -- | -- | -49.12 | -- | -- | -- |
| TriSalus Life Sciences Inc | 24.74m | -57.21m | 123.99m | 112.00 | -- | -- | -- | 5.01 | -1.70 | -1.70 | 0.8372 | -0.8892 | 1.00 | 1.23 | 7.28 | 220,848.20 | -220.73 | -- | -2,149.76 | -- | 87.65 | -- | -219.71 | -- | 2.04 | -100.87 | -- | -- | 49.31 | -- | -26.51 | -- | -- | -- |
Data as of Nov 08 2024. Currency figures normalised to Invivyd Inc's reporting currency: US Dollar USD
50.81%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Maverick Capital Ltd.as of 30 Jun 2024 | 11.77m | 9.85% |
| Deep Track Capital LPas of 30 Jun 2024 | 10.95m | 9.17% |
| M28 Capital Management LPas of 30 Jun 2024 | 9.25m | 7.74% |
| Fidelity Management & Research Co. LLCas of 30 Jun 2024 | 8.37m | 7.01% |
| The Vanguard Group, Inc.as of 30 Jun 2024 | 4.24m | 3.55% |
| BlackRock Fund Advisorsas of 30 Jun 2024 | 4.04m | 3.38% |
| Slate Path Capital LPas of 30 Jun 2024 | 3.74m | 3.13% |
| 683 Capital Management LLCas of 30 Jun 2024 | 3.63m | 3.04% |
| Redmile Group LLCas of 30 Jun 2024 | 3.07m | 2.57% |
| Geode Capital Management LLCas of 30 Jun 2024 | 1.64m | 1.37% |
More ▼
Data from 30 Jun 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
